StreetInsider.com News Articles

Form 8-K ELITE PHARMACEUTICALS For: Aug 13

Thu, 13 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26921473.html

Form 8-K ELITE PHARMACEUTICALS For: Aug 13

Thu, 13 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26921473.html

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information

Thu, 13 Aug 2026 16:11:00 -0400

Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT

Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2027 ended June 30, 2026 ("First Quarter").

Consolidated revenues for the three-month period ending June 30, 2026, were $32.4 million, a decrease of $7.9 million or approximately 19.5% as compared to the same period of the prior fiscal year in which Elite had the largest quarterly revenue in its history. Income from operations were $7.5 million, a

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information

Thu, 13 Aug 2026 16:11:00 -0400

Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT

Form 10-Q ELITE PHARMACEUTICALS For: Jun 30

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920912.html

Form 10-Q ELITE PHARMACEUTICALS For: Jun 30

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920912.html

Form 8-K/A ELITE PHARMACEUTICALS For: Aug 10

Tue, 11 Aug 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26900604.html

Form 8-K/A ELITE PHARMACEUTICALS For: Aug 10

Tue, 11 Aug 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26900604.html

Form 8-K ELITE PHARMACEUTICALS For: Aug 10

Mon, 10 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260810/26899071.html

Form 8-K ELITE PHARMACEUTICALS For: Aug 10

Mon, 10 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260810/26899071.html

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026

Mon, 10 Aug 2026 16:54:00 -0400

Financials for First Quarter of Fiscal Year 2027 Ended June 30, 2026 will be released on Thursday, August 13, 2026

Northvale, New Jersey--(Newsfile Corp. - August 10, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2027 fiscal year will be released on Thursday, August 13, 2026. Elite's management will host a live conference call on Friday, August 14^th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. Stockholders should submit their questions to

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026

Mon, 10 Aug 2026 16:54:00 -0400

Financials for First Quarter of Fiscal Year 2027 Ended June 30, 2026 will be released on Thursday, August 13, 2026

Form 8-K ELITE PHARMACEUTICALS For: Aug 04

Tue, 04 Aug 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260804/26861424.html

Form 8-K ELITE PHARMACEUTICALS For: Aug 04

Tue, 04 Aug 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260804/26861424.html

Elite Pharmaceuticals launches generic Ropinirole Extended-Release Tablets

Tue, 04 Aug 2026 07:02:14 -0400

Elite Pharmaceuticals, Inc. (OTCQB: ELTP) announced the commercial launch of its generic version of Requip XL (Ropinirole Extended-Release Tablets USP), available in 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg strengths.

Ropinirole is a non-ergoline dopamine agonist used to treat Parkinson's disease. The product is marketed and sold under the Elite Laboratories, Inc. label.

According to IQVIA data, the branded product and its equivalents recorded total U.S. sales of $10 million for the twelve months ending June 2026.

Elite Pharmaceuticals is based in Northvale, New Jersey, and operates a cGMP and DEA-registered manufacturing facility at that location.

Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL

Tue, 04 Aug 2026 07:00:00 -0400

Northvale, New Jersey--(Newsfile Corp. - August 4, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belongs to a class of drugs known as a non-ergoline dopamine agonist used to treat Parkinson's disease. This product is marketed and sold under the Elite Laboratories, Inc. label.

According to IQVIA, the branded product and its equivalents had total U.S. sales of $10

Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL

Tue, 04 Aug 2026 07:00:00 -0400

According to IQVIA, the branded product and its equivalents had total U.S. sales of $10

Form 8-K ELITE PHARMACEUTICALS For: Jun 29

Mon, 29 Jun 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260629/26707273.html

Form 8-K ELITE PHARMACEUTICALS For: Jun 29

Mon, 29 Jun 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260629/26707273.html

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information

Mon, 29 Jun 2026 16:29:00 -0400

Conference Call Scheduled for Tuesday, June 30 at 11:30 AM EDT

Northvale, New Jersey--(Newsfile Corp. - June 29, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2026 ("Fiscal 2026").

Consolidated revenues for Fiscal 2026 were $148.9 million, an increase of $64.8 million or approximately 77% as compared to the comparable period of the prior fiscal year. Income from operations was $49.1 million, an increase of $29.5 million or approximately 151% from the comparable period of the prior year. The increase in income from

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information

Mon, 29 Jun 2026 16:29:00 -0400

Conference Call Scheduled for Tuesday, June 30 at 11:30 AM EDT

Form 10-K ELITE PHARMACEUTICALS For: Mar 31

Mon, 29 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260629/26706444.html

Form 10-K ELITE PHARMACEUTICALS For: Mar 31

Mon, 29 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260629/26706444.html

Form 8-K ELITE PHARMACEUTICALS For: Jun 23

Tue, 23 Jun 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260623/26675732.html

Form 8-K ELITE PHARMACEUTICALS For: Jun 23

Tue, 23 Jun 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260623/26675732.html